Axicabtagene ciloleucelMeSH Supplementary Concept

https://ansm.sante.fr/tableau-acces-derogatoire/yescarta-0-4-2-x-108-cellules-dispersion-pour-perfusion#
2024
false
false
false
France
French
axicabtagene ciloleucel
axicabtagene ciloleucel
biological products
Antineoplastic Agents, Immunological
Recurrent High Grade B-Cell Lymphoma
lymphoma, large B-Cell, diffuse
adult
Refractory High Grade B-Cell Lymphoma
drug information
immunotherapy, adoptive
antigens, CD19

---
https://www.has-sante.fr/jcms/p_3419176/fr/yescarta-axicabtagene-ciloleucel-lymphome-diffus-a-grandes-cellules-b-ldgcb-et-lymphome-de-haut-grade-a-cellules-b-lhgcb
2023
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
insurance, health, reimbursement
axicabtagene ciloleucel
axicabtagene ciloleucel
infusions, intravenous
Recurrent Diffuse Large B-Cell Lymphoma
lymphoma, large B-Cell, diffuse
Refractory Diffuse Large B-Cell Lymphoma
Recurrent High Grade B-Cell Lymphoma
Refractory High Grade B-Cell Lymphoma
adult

---
https://www.has-sante.fr/jcms/p_3407522/fr/yescarta-axicabtagene-ciloleucel-lymphome-folliculaire
2023
false
false
false
France
lymphoma, follicular
treatment outcome
insurance, health, reimbursement
adult
Refractory Follicular Lymphoma
Recurrent Follicular Lymphoma
infusions, intravenous
axicabtagene ciloleucel
evaluation of the transparency committee
axicabtagene ciloleucel

---
https://ansm.sante.fr/tableau-marr/axicabtagene-ciloleucel
2023
false
false
false
France
French
risk management
axicabtagene ciloleucel
guidelines for drug use
axicabtagene ciloleucel
Drug-Related side effects and adverse reactions
Cytokine Release Syndrome
nervous system diseases
patient education handout
signs and symptoms
axicabtagene ciloleucel
infusions, intravenous
gene therapy

---
https://www.has-sante.fr/jcms/p_3467529/fr/yescarta-axicabtagene-ciloleucel-lymphome-diffus-a-grandes-cellules-b-ldgcb-lymphome-mediastinal-primitif-a-grandes-cellules-b-lmpgcb
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
infusions, intravenous
axicabtagene ciloleucel
Recurrent Primary Mediastinal Large B-Cell Lymphoma
Refractory Primary Mediastinal Large B-Cell Lymphoma
mediastinal neoplasms
gene therapy
Antineoplastic Agents, Immunological
Refractory Diffuse Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
adult
Anti-CD19 CAR T Cells Preparation
evaluation of the transparency committee
axicabtagene ciloleucel
lymphoma, large B-Cell, diffuse

---
https://www.has-sante.fr/jcms/p_3333446/fr/yescarta-axicabtagene-ciloleucel-lymphome-folliculaire
https://www.has-sante.fr/jcms/p_3333459/fr/decision-n-2022-0125/dc/sem-du-14-avril-2022-du-college-de-la-haute-autorite-de-sante-portant-autorisation-d-acces-precoce-de-la-specialite-yescarta
2022
false
false
false
France
Recurrent Follicular Lymphoma
Refractory Follicular Lymphoma
insurance, health, reimbursement
treatment outcome
gene therapy
infusions, intravenous
axicabtagene ciloleucel
adult
evaluation of the transparency committee
axicabtagene ciloleucel
lymphoma, follicular

---
https://www.has-sante.fr/jcms/p_3358972/fr/yescarta-axicabtagene-ciloleucel-lymphome-diffus-a-grandes-cellules-b
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
Refractory Diffuse Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
infusions, intravenous
axicabtagene ciloleucel
guidelines for drug use
adult
evaluation of the transparency committee
axicabtagene ciloleucel
lymphoma, large B-Cell, diffuse

---
https://www.has-sante.fr/jcms/p_3262244/fr/yescarta-axicabtagene-ciloleucel
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
axicabtagene ciloleucel
adult
lymphoma, large B-Cell, diffuse
mediastinal neoplasms
recurrence
Primary mediastinal (thymic) large B-cell lymphoma (disorder)
Primary Mediastinal Large B-Cell Lymphoma
infusions, intravenous
Anti-CD19 CAR T Cells Preparation
Recurrent Primary Mediastinal Large B-Cell Lymphoma
antigens, CD19
Receptors, Chimeric Antigen
t-lymphocytes
evaluation of the transparency committee
axicabtagene ciloleucel
antigens, CD19
immunotherapy, adoptive
immunotherapy, adoptive

---
https://www.inesss.qc.ca/publications/repertoire-des-publications/publication/avis-sur-laxicabtagene-ciloleucel-pour-le-traitement-des-lymphomes-a-grandes-cellules-b-recidivants-ou-refractaires.html
2019
false
true
false
false
Canada
Diffuse large B-cell lymphoma recurrent
Diffuse large B-cell lymphoma refractory
axicabtagene ciloleucel
technical report
axicabtagene ciloleucel
lymphoma, large B-Cell, diffuse
immunotherapy, adoptive
antigens, CD19

---
https://www.has-sante.fr/portail/jcms/c_2888882/fr/yescarta
https://www.has-sante.fr/portail/jcms/c_2888882/fr/yescarta-axicabtagene-ciloleucel-car-t-anti-cd19
2018
false
false
false
France
French
treatment outcome
evaluation of the transparency committee
adult
lymphoma, large B-Cell, diffuse
mediastinal neoplasms
recurrence
antigens, CD19
receptors, antigen, t-cell
immunotherapy, adoptive
immunotherapy, adoptive
survival analysis
t-lymphocytes
Primary mediastinal (thymic) large B-cell lymphoma (disorder)
t-lymphocytes
receptors, antigen, t-cell
guidelines for drug use
axicabtagene ciloleucel
axicabtagene ciloleucel
axicabtagene ciloleucel

---
https://www.ema.europa.eu/medicines/human/EPAR/Yescarta
2018
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
orphan drug production
axicabtagene ciloleucel
adult
lymphoma, large B-Cell, diffuse
Primary mediastinal (thymic) large B-cell lymphoma (disorder)
infusions, intravenous
product surveillance, postmarketing
immunotherapy
antigens, CD19
receptors, antigen, t-cell
t-lymphocytes
t-lymphocytes
aged
pregnancy
breast feeding
axicabtagene ciloleucel
axicabtagene ciloleucel

---